BioSpace News Archive

Cellectis S.A. today announced results for the three-month and nine-month periods ending September 30, 2021.

Tivity Health, Inc. (Nasdaq: TVTY) today announced that it will participate in the following virtual investor conference: The Credit Suisse Annual Healthcare Conference

Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA ® Electronic Health Records System

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported financial results for the third quarter of 2021.

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, reported financial results for the third quarter ended September 30, 2021.

Opiant Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for OPNT003, nasal nalmefene, its investigational treatment for opioid overdose.

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and review recent business highlights.

T2 Biosystems, Inc.T2 Biosystems, Inc.T2 Biosystems, Inc.T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced financial results for the three months ended September 30, 2021.

Zogenix, a global biopharmaceutical company developing rare disease therapies, announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update.

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period ended September 30, 2021.